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The epidermal growth factor receptor (EGFR) is a member of the tyrosine kinase receptor family
involved in signal transduction and the regulation of cellular proliferation and differentiation. It
is also a calmodulin-binding protein. To examine the role of calmodulin in the regulation of EGFR,
the effect of calmodulin antagonist, W-13, on the intracellular trafficking of EGFR and the MAPK
signaling pathway was analyzed. W-13 did not alter the internalization of EGFR but inhibited its
recycling and degradation, thus causing the accumulation of EGF and EGFR in enlarged early
endosomal structures. In addition, we demonstrated that W-13 stimulated the tyrosine phosphor-
ylation of EGFR and consequent recruitment of Shc adaptor protein with EGFR, presumably
through inhibition of the calmodulin-dependent protein kinase II (CaM kinase II). W-13–mediated
EGFR phosphorylation was blocked by metalloprotease inhibitor, BB94, indicating a possible
involvement of shedding in this process. However, MAPK activity was decreased by W-13;
dissection of this signaling pathway showed that W-13 specifically interferes with Raf-1 activity.
These data are consistent with the regulation of EGFR by calmodulin at several steps of the
receptor signaling and trafficking pathways.
INTRODUCTION
The epidermal growth factor (EGF) binds to its receptor
(EGFR) at the plasma membrane. On binding, EGFR dimer-
izes, its intrinsic tyrosine kinase is activated, and specific
tyrosine-containing residues in its cytoplasmic tail are auto-
phosphorylated (Carpenter, 2000). Current models propose
that a pool of EGFR is located in caveolae (Carpenter, 2000).
On ligand binding, EGFR migrates out of caveolae and is
internalized via clathrin-coated pits. During this transit the
receptor activates the Ras/mitogen-activated protein kinase
(MAPK) pathway through binding to Grb2, tyrosine phos-
phorylation of the adaptor protein Shc, subsequent forma-
tion of Shc-Grb2-Sos complex, and induction of Ras activity.
EGF/EGFR complexes are rapidly internalized through re-
ceptor-mediated endocytosis and transported into the endo-
cytic compartment, where signaling is continued (Di
Guglielmo et al., 1994; Herbst et al., 1994; Vieira et al., 1996;
Pol et al., 1998; Haugh et al., 1999; Pol et al., 2000a, 2000b)
until ligand and receptor are sorted and eventually de-
graded (Carpentier et al., 1987; Felder et al., 1990; Sorkin,
1998).
As occurs with other receptors, the cytoplasmic tail of the
EGFR contains several functional domains, which are the
targets for PKC and calmodulin-dependent protein kinase II
(CaM kinase II) phosphorylation or binding to adaptor pro-
teins (Grb2, Shc) or other proteins involved in its functioning
or related with intracellular trafficking or signaling. Among
these functional domains, there is a calmodulin-binding re-
gion (645–660 amino acids) in the juxtamembrane domain
(Martı´n-Nieto and Villalobo, 1998); interestingly, this region
also shows a di-leucine motif, interacts with IP3-K and the
s-subunit of G-proteins, and contains the threonine 654, the
target of PKC. Calmodulin binding inhibits EGFR tyrosine
kinase activity in vitro (San Jose´ et al., 1992) and PKC-
induced phosphorylation at Thr-654 (Lund et al., 1990; Bao et
al., 2000). Finally, binding of EGF increases cytoplasmic
Ca2, which in turn, may be responsible for calmodulin
binding and activation. The agents that increase cytosolic
calcium significantly inhibit EGFR tyrosine kinase activity.
This may be partially due to CaM kinase II–mediated phos-
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phorylation at serines 744 or 1046/1047 (Feinmesser et al.,
1999). Moreover, calcium increase is also associated with
activation of Pyk2 and is responsible for the tyrosine phos-
phorylation of EGFR (Dikic et al., 1996; Leserer et al., 2000).
Calmodulin, the most ubiquitous calcium-binding protein
in nonmuscular cells, regulates proliferation, cell growth,
and movement, among others (Klee et al., 1980; Chin and
Means, 2000). In recent years, several reports have suggested
that calmodulin is also involved in membrane trafficking, in
both endocytic and exocytic pathways. Treatment of cells
(NRK, MDCK, HepG2, COS-1) with calmodulin antagonists
(W-7, W-13; Hidaka and Tanaka, 1985) leads to the forma-
tion of large endosomes containing endocytosed ligands
(fluid phase and receptor-mediated; Apodaca et al., 1994; de
Figueiredo and Brown, 1995; Llorente et al., 1996). Because
recycling of transferrin is inhibited and ligands remain in
these large early endocytic structures, it is deduced that
W-13 blocks the exit (budding) from early endosomes. This
morphological effect cannot be reproduced by treatment of
cells with KN-93, a specific CaM kinase II inhibitor.
In MDCK cells and hepatocytes, pIgR interacts with cal-
modulin as shown by direct binding assays and affinity
chromatography (Chapin et al., 1996; Enrich et al., 1996). In
pIgR-expressing MDCK cells treated with calmodulin antag-
onists, pIgA transcytosis and recycling of transferrin were
inhibited (Apodaca et al., 1994). In the same cells, calmodulin
was implicated in the endocytosis and trafficking of ricin
(Llorente et al., 1996).
Additional evidence for the involvement of calmodulin in
the regulation of membrane trafficking includes the follow-
ing: EEA1, a crucial component of early endosomal docking
and fusion events, has a calmodulin IQ motif (Mu et al., 1995;
Mills et al., 2001); calmodulin is also involved in the fusion of
endosomes (Emans and Verkman, 1996; Mayorga et al., 1996;
Colombo et al., 1997; Quetglas et al., 2000) and has been
detected in isolated endosomal fractions of rat liver (Enrich
et al., 1988), and in caveolae (Shaul et al., 1996). Furthermore,
calmodulin interacts with -actinin and clathrin (Merisko et
al., 1988), and it may be functionally involved in the forma-
tion of clathrin-coated pits (Salisbury et al., 1980). Finally, we
recently reported that Ras binds to calmodulin and modu-
lates its activity (Villalonga et al., 2001); different isoforms of
Ras have been localized in endocytic fractions (Ali and
Evans, 1990; Pol et al. 1998).
In spite of all this evidence, the precise role of calmodulin
in these events and its consequences for the possible cross-
talk between signaling pathways are unknown. Here, we
show that in COS-1 cells both W-13 and KN-93 activate the
tyrosine phosphorylation of EGFR in the absence of EGF.
However, W-13 inhibited MAPK phosphorylation, whereas
KN-93 did not. This may account for the multiple/(sequen-
tial) effect of calmodulin (antagonists) on the EGFR traffick-
ing/signaling pathway: first, regulating the morphology of
the endocytic compartment (formation of large early endo-
somes) and impairing the recycling of EGFR, perhaps
through cytoskeletal-associated CaMBPs; second, regulating
the functioning/signaling of EGFR, CaM kinase II, and
Raf-1; and third, mediating the shedding of growth factor(s),
possibly through the inhibition of CaM kinase II, which may
be responsible for the subsequent extracellular EGFR trans-
activation.
MATERIALS AND METHODS
Reagents
Mouse receptor-grade EGF, W-13, W-12, and Tyrphostin (AG-1478)
were from Sigma Chemical Co. (Madrid, Spain). KN-93, KN-92
inhibitors were from Calbiochem (Nottingham, UK). EGF conju-
gated with TRITC (EGF-TRITC) and transferrin conjugated with
FITC (Tf-FITC) were from Molecular Probes (Eugene, OR). An mAb
to the extracellular domain of the EGFR was obtained from ATCC
(American Type Culture Collection, Rockville, MD); monoclonal
antibodies to EEA1 and Raf-1 were from Transduction Laboratories
(Lexington, KY). The rabbit polyclonal antibodies against phosphor-
ylated MAPK or phosphorylated MEK were from Cell Signaling,
New England Biolabs, (Beverly, MA), the monoclonal anti–(pan)-
Ras was from Oncogene Sciences Inc. (Cambridge, MA), and the
rabbit polyclonal anti–PDGF-R (type A/B) antibody was from Up-
state Biotechnology (UBI, Lake Placid, NY). Peroxidase-labeled an-
tibodies and SDS-PAGE molecular weight markers were from Bio-
Rad (Hercules, CA). Batimastat (BB94) was from British Biotech
(UK). 125I-EGF was prepared as described in Carter and Sorkin
(1998).
Cell Culture
Green monkey kidney cells (COS-1) with 4  105 EGFR/cell were
grown in DMEM containing 10% fetal calf serum (FCS), antibiotics,
and glutamine. DMEM and FCS were purchased from Biological
Industries (Beit Haemek, Israel). Cells were grown to 90% conflu-
ence for immunoprecipitation and lysates experiments or 50% con-
fluence for immunofluorescence experiments. In some experiments
we also used NIH3T3 and Rat-1 cells.
Immunoprecipitation
COS-1 cells grown on 60-mm dishes were treated or not with EGF
(100 ng/ml) or PDGF (20 ng/ml) and W-13 or W-12 in binding
medium (DMEM, 0.1% bovine serum albumin [BSA], 20 mM
HEPES, pH 7.3). Cells were then washed in phosphate-buffered
saline (PBS) and solubilized by scraping with a rubber policeman in
TGH buffer (1% Triton X-100, 10% glycerol, 50 mM NaCl, 50 mM
HEPES, pH 7.3, 1 mM EDTA, 1 mM EGTA, 1 mM sodium or-
thovanadate, 10 mM sodium fluoride, 1 mM phenylmethylsulfonyl
fluoride [PMSF], 10 mg/ml leupeptin, 10 mg/ml aprotinin) fol-
lowed by gentle rotation for 10 min at 4°C. Lysates were then
centrifuged at 14,000  g for 10 min at 4°C. Supernatants were
incubated with anti-EGFR (Ab225), anti–PDGF-R (UBI), or anti–P-
tyrosine (PY20; Transduction Laboratories) for 3 h at 4°C and then
for 30–60 min after the addition of Protein A or G-Sepharose
(Pierce, Rockford, IL). Normal rabbit IgG was used for nonspecific
controls. Immunoprecipitates were washed twice in TGH supple-
mented with 100 mM NaCl and then once without NaCl. SDS-
polyacrylamide gels, 8%, were used to separate proteins. Proteins
were then transferred to Immobilon-P (Millipore, Bedford, MA) and
immunoblotted using antiphosphotyrosine-RC20 HRP-conjugated
(Transduction Laboratories) or rabbit polyclonal anti-EGFR anti-
body (antibody 1005; Santa Cruz Biotechnology, Santa Cruz, CA)
followed by the appropriate peroxidase-conjugated secondary anti-
body and ECL detection (Amersham Pharmacia Biotechnology,
Buckinghamshire, UK).
Cellular Extracts
After the various treatments (as indicated in figure legends), COS-1
cells were lysed in a buffer containing 2% SDS, 67 mM Tris-HCl, pH
6.8, and 10 mM EDTA, and sonicated twice for 10 s. Equal amounts
of protein were electrophoresed and immunoblotted (Lowry et al.,
1951).
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Immunofluorescence Staining
Cells grown on coverslips and incubated with W-13 or labeled
ligands (EGF-TRITC, Tf-FITC) were fixed with freshly prepared 4%
paraformaldehyde for 12 min at room temperature and mildly
permeabilized with PBS containing 0.1% Triton X-100, 0.1% BSA at
room temperature for 3 min. Coverslips were then incubated in the
same buffer, in which Triton X-100 was omitted, at room tempera-
ture for 1 h with the primary antibody, washed intensively, and
then incubated with adequate secondary antibodies labeled with
FITC, Cy3, or Cy5 (Jackson ImmunoResearch Laboratories, Inc.,
West Grove, PA). Both primary and secondary antibody solutions
were precleared by centrifugation at 14,000  g for 10 min. After
staining, the coverslips were mounted in Mowiol (Calbiochem), and
a confocal microscope ( TCS NT or SP; Leica, Heerbrugg, Switzer-
land) was used to record the images. Final analysis of all images was
performed using Adobe Photoshop 5.5 (Adobe Systems, San Jose,
CA).
Measurement of Ras Activation
The capacity of Ras-GTP to bind to RBD (Ras-binding domain of
Raf-1) was used to analyze the amount of active Ras (de Rooij and
Bos, 1997). Cells (2  10 6) were lysed in the culture dish with lysis
buffer (20 mM Tris-HCl, pH 7.5, 2 mM EDTA, 100 mM NaCl, 5 mM
MgCl 2, 1% [vol/vol] Triton X-100, 5 mM NaF, 10% [vol/vol]
glycerol, 0.5% [vol/vol] 2-mercaptoethanol) plus protease and phos-
phatase inhibitors. Cleared lysate (10,000  g) was assayed for
protein concentration by the Bradford (1976) method and protein-
equalized supernatants were incubated for 2 h at 4°C with glutathi-
one sepharose-4B beads precoupled with GST-RBD. Beads were
washed four times in the lysis buffer. Bound proteins were solubi-
lized by the addition of 30 l of Laemmli (1980) loading buffer and
run on 12.5% SDS-PAGE gels. The amount of Ras in the bound
fraction was analyzed by Western blotting as described above using
anti–(pan)-Ras (antibody-3, OP-40; Oncogene Sciences) mAb.
Raf-1 Kinase Activity Assays
To measure Raf-1 activity, kinase assays were performed after im-
munoprecipitation as described (Marais et al., 1998). Briefly, treated
cells (2  10 6) were harvested on ice in lysis buffer (50 mM
Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM CaCl2, 1% [vol/vol] Triton
X-100, 5 mM NaF, 0.1 mM Na3VO4, 1 mM PMSF, 1 mM aprotinin,
and 20 M leupeptin) and clarified by centrifugation at 10,000  g.
Supernatants (equalized for protein concentration) were then im-
munoprecipitated for 2 h at 4°C with 2 g of anti–Raf-1 precoupled
with 20 l of protein G-sepharose. Immunoprecipitates were then
washed three times in buffer (30 mM Tris, 0.1 mM EDTA, 0.3%
mercaptoethanol, 10% glycerol, 0.1% [vol/vol] Triton X-100, 5 mM
NaF, 0.2 mM Na3VO4) with decreasing amounts of NaCl (high: 1 M,
low: 0.1 M and salt-free). Washed immunoprecipitates were incu-
bated for 30 min at 30°C in 20 l of MEK buffer (30 mM Tris, 0.1 mM
EDTA, 0.3% mercaptoethanol, 10 mM MgCl2, 0.1% [vol/vol] Triton
X-100, 5 mM NaF, 0.2 mM Na3VO4, 0.8 mM ATP, 6.5 g/ml GST-
MEK, 100 g/ml GST-ERK2), and the reaction was terminated by
the addition of 20 l of ice-cold stop buffer (30 mM Tris, 6 mM
EDTA, 0.3% mercaptoethanol, 0.1% [vol/vol] Triton X-100, 5 mM
NaF, 0.2 mM Na3VO4). After centrifugation, 6-l aliquots of super-
natants were incubated for 15 min at 30°C with 24 l of MBP buffer
(50 mM Tris, 0.1 mM EDTA, 0.3% mercaptoethanol, 10 mM MgCl2,
0.1% [vol/vol] Triton X-100, 5 mM NaF, 0.2 mM Na3VO4, 0.1 mM
ATP, 2.5 l 32P-ATP, 0.5 g/l MBP, 0.16 g/l BSA), and then 24
l was loaded on P81 sheets, washed three times (20 min each) in 75
mM orthophosphoric acid, and counted for 32P incorporation.
Expression of EGFR-Cyan Fluorescent Protein and
Yellow Fluorescent Protein-Shc, and FRET
Microscopy
The preparation of EGFR-cyan fluorescent protein (CFP) and por-
cine aortic endothelial (PAE) cells constitutively expressing EGFR-
CFP are described elsewhere (Sorkin et al., 2000). The generation of
yellow fluorescent protein (YFP)-Shc is also reported (Sorkin, 2001).
For fluorescence resonance energy transfer (FRET) analysis, YFP-
Shc was transiently expressed in PAE/EGFR-CFP cells. The visual-
ization of fluorescent proteins, digital imaging, and FRET measure-
ments were performed as described (Sorkin et al., 2000; Sorkin,
2001).
Internalization, Recycling, and Degradation of
125I-EGF
Internalization of 125I-EGF was measured as described (Sorkin et al.,
1996). Briefly, cells cultured in 12-well dishes were incubated with
125I-EGF (1 ng/ml) in binding medium (DMEM, 20 mM HEPES,
0.1% BSA) at 37°C for 1–10 min. After the times indicated, the
medium was aspirated and the monolayers were rapidly washed
three times in cold DMEM to remove unbound ligand and then
incubated for 5 min with 0.2 M acetic acid (pH 2.8) containing 0.5 M
NaCl at 4°C. The acid wash was used to determine the amount of
surface-bound 125I-EGF. Finally, the cells were lysed in 1 N NaOH
to measure internalized radioactivity. The ratio of internalized to
surface radioactivity was plotted against time. Nonspecific binding
was measured for each time-point in the presence of 100-fold molar
excess of unlabeled EGF and was not more than 5–10% of total
counts.
125I-EGF recycling and degradation was measured as described
(Kornilova et al., 1996). Briefly, cells in 35-mm culture dishes were
incubated with 5 ng/ml 125I-EGF for 7 min at 37°C and washed in
cold DMEM. The 125I-EGF that had not been internalized during
37°C incubation was removed from the cell surface by a 2.5-min acid
wash (0. 2 M sodium acetate, 0.5 M NaCl, pH 4.5). At this point cells
are referred to as “ 125I-EGF-loaded cells.” Trafficking of 125I-EGF-
receptor complexes in these loaded cells was then initiated by
incubating the cells in fresh binding medium containing 200 ng/ml
unlabeled EGF at 37°C for 0–60 min. Excess of unlabeled EGF in the
medium and at the surface prevented rebinding and reinternaliza-
tion of recycled 125I-EGF. At the end of the chase incubation, the
medium was collected to measure the amount of intact and de-
graded 125I-EGF by precipitation with trichloracetic acid (TCA), and
cells were subjected to the acid wash (pH 2.8) as described in
internalization experiments to determine the amount of surface-
bound 125I-EGF. Finally, cells were solubilized in 1N NaOH to
measure the amount of intracellular 125I-EGF. The amount of recy-
cled 125I-EGF was estimated by summing the radioactivity counted
on the cell surface and the TCA-precipitated radioactivity in the
medium during chase incubation, and the recycling rate was ex-
pressed as ratio of this sum to the intracellular EGF molecules. The
degradation rate was calculated as the ratio of the amount of de-
graded 125I-EGF (TCA-soluble) in the medium to the amount of
intracellular radioactivity at each time point.
RESULTS
To examine the role of calmodulin in the trafficking and
signaling of EGFR we treated COS-1 cells with calmodulin
antagonist, W-13, and the morphology of endocytic com-
partment and the subsequent activation of the MAPK sig-
naling pathway were analyzed. The use of W-13 has been
demonstrated highly specific for calmodulin and it does not
mimic the effect shown by inhibitors of CaMPKs or PKC
(Hidaka and Tanaka, 1985).
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Morphology and Trafficking at the Endocytic
Compartment in Cells Treated with W-13
We already reported the effect of W-13 on the morphology of
endocytic compartment, in MDCK cells (Apodaca et al.,
1994). COS-1 cells were used in the present study, and the
trafficking of EGFR was analyzed. Cells were starved over-
night (0.5% FCS), and experiments were performed with or
without activation with EGF (100 ng/ml, 30 min at 37°C), as
indicated.
Using an antibody to EGFR (Ab225, to the extracellular
domain) it was observed that in control cells and in cells
treated with W-12, EGFR was mainly detected at the plasma
membrane. However, in cells treated with W-13 (10 g/ml)
almost all EGFR was seen in randomly distributed large
endocytic structures. When cells were incubated with EGF
(30 min at 37°C), EGFR was distributed in small endocytic
structures in the Golgi/lysosome region (Figure 1A). The
accumulation of EGFR in aberrant early endosomes was also
observed during the constitutive recycling of EGFR (Figure
1B). In this experiment COS-1 cells were immunolabeled
with a monoclonal anti-225 and were not activated with
EGF. In nonpermeabilized cells, quantification of surface
labeling indicated an 42% average diminution after W-13
treatment.
To determine whether these enlarged endocytic struc-
tures, containing the EGFR, were derived from early or late
endosomes, we analyzed the distribution of the early endo-
somal marker, EEA1, and internalized transferrin (Tf-FITC)
and EGF (EGF-TRITC) after 15 min. Figure 1, C and D,
shows, in a triple labeling experiment, that anti-EEA1
and/or anti-EGFR (Figure 1D) colocalize with transferrin-
FITC and/or EGF-TRITC in the enlarged endocytic struc-
tures. The specific inhibition of the clathrin-coated pit recep-
tor–mediated endocytosis, by overexpression of an eps15
mutant, impaired the transport of EGFR to the morpholog-
ically modified early endosomes of W-13–treated cells.
These results indicate that W-13 affects the morphology and
the function of the early endocytic compartment involved in
the recycling of EGFR.
W-13 Blocks the EGFR Trafficking in Endosomes
Immunofluorescence analysis of cells treated with W-13 re-
vealed accumulation of EGFRs in early endosome-like ves-
icles, many of which were enlarged (Figure 1). Indeed, bind-
ing experiments using 125I-EGF showed that incubation of
cells with W-13 decreased the number of EGF binding sites
at the cell surface by 30–40% (Figure 2A). The downregula-
tion and accumulation of receptors in endosomes may be
due to W-13 effect on two processes: accelerated internaliza-
tion of EGFRs and inhibition of their recycling from endo-
somes to the surface.
W-13 inhibits the exit of transferrin receptor from endo-
somes (Apodaca et al., 1994). Therefore, we next tested, by
quantitative analysis, whether W-13 also affects recycling of
EGFRs from endosomes to plasma membrane. Because the
mechanism of recycling is believed to be the same for unoc-
cupied and occupied EGF receptors, we analyzed the effect
Figure 1. Calmodulin antagonist, W-13, produces enlarged early
endosomes containing EGFR, EEA1, EGF, and transferrin. (A) COS-1
cells grown on coverslips were incubated with W-12/W-13 (10 g/
ml) or 100 ng/ml EGF for 30 min, fixed, and stained with anti-EGFR
(Ab225) followed by a goat anti-mouse secondary antibody labeled
with Cy3. (B) W-13 inhibits the recycling of nonoccupied EGFR; cells
were preincubated with anti-EGFR (Ab225, 10 g/ml) for 20 min at
4°C, washed, and incubated with W-13 for 60 min at 37°C. Inset: a
detail of enlarged endosomes after W-13 treatment. (C) Triple labeling
was used to analyze the location of Tf-FITC and EGF-TRITC with the
early endosomal marker anti-EEA1 (anti-mouse Cy5). (D) Alternatively, EGF-TRITC can also be observed together with EEA1 and EGFR. Confocal
microscope was used to acquire the images. The projections of six optical sections are shown. CTRL, control nontreated cells. Bar, 10 m.
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of W-13 on recycling of 125I-EGF. To directly measure the
recycling rates, cells were loaded with 125I-EGF at 37°C, the
remaining surface 125I-EGF was removed by mild acid wash,
and the recycling of 125I-EGF was measured by the appear-
ance of intact 125I-EGF radioactivity in the medium and at
the cell surface as described elsewhere (Kornilova et al., 1996;
see MATERIALS AND METHODS). Recycling of 125I-EGF
was severely inhibited in the presence of W-13 (Figure 2B).
Degradation of 125I-EGF was completely blocked in cells
incubated with W-13 (Figure 2C). These data suggest that
W-13 affects the transport of EGFR and EGF-EGFR com-
plexes from endosomes to cell surface and lysosomes.
Because of the rapid recycling of unoccupied receptors, it
is difficult to measure the specific rates of internalization of
unoccupied EGFRs. Hence we tested the effect of W-13 on
internalization of 125I-EGF-occupied EGFRs. Uptake of EGF
was not significantly affected during the first 6 min of en-
docytosis but increased later (Figure 2D). The uptake of EGF
is the sum of two processes: internalization and recycling.
During short initial endocytosis the contribution of recycling
to the overall uptake kinetics is negligible because the inter-
nalized pool of EGF is very small. Therefore, the internal-
ization rate measured at very early time points reflects the
specific internalization rate, which is not affected by W-13.
The effect of W-13 on uptake at later time points may be due
to inhibition of recycling, which begins to contribute in the
uptake measurement at these time points. The results of the
kinetics analysis of 125I-EGF endocytosis and immunofluo-
rescence experiments indicate that the main effect of W-13
on EGFR trafficking occurs at the level of endosomes.
Calmodulin Antagonist, W-13, Stimulates Tyrosine
Phosphorylation of EGFR but Impairs ERK
Phosphorylation
To examine the role of calmodulin in the tyrosine kinase
activity of EGFR and in the downstream signaling pathway
to the MAP kinase activation, we used COS-1 cells treated
with W-13 for 30 min at different concentrations of W-13
(0.5–15 g/ml). Lysates were prepared and analyzed by
Western blotting with a monoclonal antiphosphotyrosine
antibody, and the same membranes were stripped and re-
probed with a polyclonal anti- EGFR antibody. Figure 3A
shows a dose-dependent increase in the phosphotyrosine
with increasing amount of W-13; the band at 170 kDa cor-
responded to the EGFR.
To further demonstrate the stimulation of EGFR phospho-
tyrosine by W-13, lysates of COS-1 cells were immunopre-
cipitated with anti-EGFR (Ab225) and analyzed by Western
blotting using an antiphosphotyrosine antibody. Controls
Figure 2. Effect of W-13 on
125I-EGF internalization, recy-
cling and degradation. COS-1
cells were incubated, in the
presence of 10 g/ml W-13 (E)
or vehicle DMSO (F), with 1–5
ng/ml 125I-EGF for 1–10 min or
1–60 min to measure internal-
ization (D) or downregulation
(A), recycling (B), or degrada-
tion (C). The amount of surface-
bound, internalized, or intact
radioactivity in the medium
was determined as described in
MATERIALS AND METHODS.
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using W-12 as well as an irrelevant IgG were performed.
Figure 3B shows a representative experiment in which
EGF-R from W-13/W-12 (10 g/ml) or EGF-treated cells
were immunoprecipitated, and the extent of tyrosine phos-
phorylation of the receptors was examined by immunoblot-
ting with P-tyr antibody. As shown in Figure 3C, the amount
of phosphotyrosine in the EGFR in cells treated with W-13
was up to 20% of the maximal amount achieved in cells
stimulated with EGF. Immunoprecipitation of tyr-P-EGFR in
cells stimulated with EGF yields approximately 50–60% of
the total pool compared with the 5–10% retrieved after W-13
treatment.
To confirm the specificity of W-13 effect on the EGFR, we
analyzed whether the calmodulin antagonist affected the tyr
phosphorylation of another growth factor receptor, the
platelet derived growth factor receptor (PDGF-R). Because
COS-1 cells express very low levels of PDGF-R, NIH3T3 (as
well as Rat-1) cells were used. As shown in Figure 3D, no
increase in the tyrosine phosphorylation of the PDGF-R can
be observed after the treatment with W-13.
To determine whether the increased tyrosine phosphory-
lation of EGFR was functional after the W-13 treatment, we
analyzed, in living cells, the spatiotemporal interactions of
EGFR and Shc by FRET microscopy, using EGFR fused to
CFP and Shc fused to YFP. Figure 4A shows that the in-
creased phosphorylation produced by W-13 led to the asso-
ciation of EGFR-CFP with adaptor protein Shc-YFP (the
same was observed with Grb2). After a 30-min incubation of
cells with W-13, both EGFR-CFP and YFP-Shc were seen
concentrated in large endocytic structures. Efficient FRET
signals were observed, indicating that YFP-Shc was bound
to the EGFR-CFP.
Thus, data in Figures 3 and 4 demonstrate that the inhi-
bition of calmodulin leads to tyrosine phosphorylation of
EGFR, accumulation of phosphorylated receptors in endo-
somes where they are capable of interaction with effector
proteins. However, the stimulation of EGFR tyrosine phos-
phorylation did not correlate with the phosphorylation of
ERK. Indeed, when cells were treated with W-13 and their
lysates were analyzed by Western blotting with phospho-
ERK antibodies, it was observed that the amount of basal
ERK-P was diminished, when compared with samples
treated with W-12 or control (untreated) cells (Figure 4B).
These data suggested that the calmodulin antagonist W-13
stimulate the Tyr-kinase activity of EGFR (autophosphory-
lation). To test this hypothesis, COS-1 cells were pretreated
with tyrphostin, a specific inhibitor of the EGFR Tyr-kinase
activity (AG1478, 1 M for 15 min) and then incubated with
Figure 3. W-13 increases ty-
rosine phosphorylation of EGFR.
(A) Cells were incubated with the
indicated concentration of W-13
for 30 min at 37°C, and an equal
amount of protein was electro-
phoresed and analyzed by West-
ern blotting with antiphosphoty-
rosine RC-20 antibody HRP-
conjugated or with Ab1005, for
the EGFR. (B) EGFR was immu-
noprecipitated with monoclonal
antibody 225 from TGH lysates
of COS-1 cells treated with W12
or W-13 (10 g/ml) for 60 min or
100 ng/ml EGF for 10 min at
37°C. Nonspecific mouse IgG
was used as control (ctrl). Immu-
noprecipitates were resolved by
SDS-PAGE and tyrosine phos-
phorylated EGFR was detected
with RC-20 HRP-conjugated an-
tibody. To quantify the tyrosine
phosphorylation of EGF-R,
COS-1 cells were incubated with
W-13/W-12 (10 g/ml) for 60
min or EGF 100 (ng/ml) for 10
min at 37°C. Equal amount of
protein (lysates) were electropho-
resed and phosphotyrosine de-
tected by Western blotting. (C)
The quantification of densitomet-
ric values (n  9). The amount of
EGF-R tyrosine phosphorylation
was determined as a percentage
of the phosphorylation obtained
with the maximum concentration
of EGF. The effect of W-12/W-13
on the tyrosine phosphorylation
of the PDGF-R was considered as control of specificity. (D) Treatment with W-13 does not affected the tyrosine phosphorylation of PDGF-R,
demonstrated by immunoprecipitation of COS-1 or NIH3T3 lysates with an anti–PDGF-R antibody.
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or without EGF and/or W-13. No increase of tyr phos-
phorylation was detected in samples treated with tyr-
phostin plus W-13 or with EGF (Figure 5A). A similar
effect was observed when EGFR was incubated with an-
tibody antibody-225, which blocked the binding site for
EGF and therefore the extracellular activation of EGFR. In
samples pretreated with antibody-225 (10 g/ml), W-13
or EGF did not increase the tyr phosphorylation of EGFR
(Figure 5B). Interestingly, when the same membrane was
reprobed with anti MEK-P in samples treated with anti-
body-225, MEK-P was significantly inhibited (Figure 5C).
In summary, the intrinsic EGFR kinase activity is neces-
sary for the increase on tyr phosphorylation observed in
W-13–treated cells. Moreover, W-13 did not affect the
activation of EGFR by intracellular transactivation.
Raf-1 Is Responsible for the Impairment of EGFR-
mediated ERK Activation by W-13
To dissect the downstream signaling pathway of EGFR re-
sponsible for the blockage of ERK phosphorylation by W-13,
we analyzed the amount of Ras-GTP, by means of a pull
down assay with GST-RBD (Ras binding domain). Starved
COS-1 cells were treated with W-13 for 1 h, and in the last 15
min EGF (0, 5, 100 ng/ml) was added. Lysates from
various conditions were split and used for Western blot-
ting with antiphosphotyrosine, anti–MEK-P or used for
pull down experiments with GST-RBD followed by im-
munoblotting of the bound material with anti–Pan-Ras
antibody. Figure 6B shows a representative experiment in
which W-13 causes a moderate increase (26.33  3.82%,
n  3) in the amount of Ras-GTP (in cells not stimulated
with EGF), whereas the amount of P-MEK decreased more
significantly (Figure 6C).
The involvement of calmodulin was confirmed by mea-
suring the Raf-1 activity by immunoprecipitation with
monoclonal anti-Raf and the kinase cascade assay, using
GSTMEK-1, GSTERK2, and myelin basic protein (MBP) as
substrates. W-13 significantly decreased Raf-1 activity irre-
spective of EGF stimulation (Figure 7A). Thus W-13 may
additionally interfere at the level of Raf-1 activity. Indeed,
other studies have described that Raf-1 interacts with cal-
modulin (Egea et al., 2000). However, W-13 did not affect (or
slightly increase) the interaction of Ras and Raf, as revealed
by coimmunoprecipitation of Raf with anti–pan-Ras anti-
body (Figure 7B). Lysates of the same experiment were
probed with anti–P-MEK and, as shown before, inhibition of
P-MEK was detected with W-13 (Figure 7C).
Figure 4. W13 stimulates Shc-
EGF-R interaction in vivo and
inhibits MAPK activation. (A)
Shc-YFP was transiently ex-
pressed in PAE/EGFR-CFP cells
and incubated with W-13 for 30
min at 37°C. Images were ac-
quired with CFP (left column)
and YFP (central column) filter
sets before (time 0, Ctrl) and af-
ter W-13 incubation. FRETC (cor-
rected FRET) was calculated and
presented as quantitative
pseudocolor image (right col-
umn). YFP and CFP images were
background-subtracted. Inset:
high-resolution image of an en-
dosome. A.l.u.f.i., arbitrary lin-
ear units of fluorescence inten-
sity. (B) COS-1 cells starved
overnight were incubated with
W-13 or W-12 (10 g/ml) for 60
min at 37°C. An equal amount of
protein (lysates) was electropho-
resed and phosphotyrosine or
phospho-MAPK (P-Erks) de-
tected by Western blotting with
antiphosphotyrosine RC-20 anti-
body HRP-conjugated or an-
tiphospho-42/44 antibody (P-
MAPK) followed by the
appropriate peroxidase-conju-
gated secondary antibodies and
ECL detection.
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Dual Effect of Calmodulin on the Regulation on
EGFR Signaling
Although EGFR is a calmodulin-binding protein and the
effects of calmodulin on the kinase activity of EGFR have
been described elsewhere, calmodulin may act directly or
through the CaM kinase II and therefore regulate the phos-
phorylation of specific serines in the cytoplasmic domain of
the receptor (Feinmesser et al., 1999). We used KN-93 as a
specific inhibitor of CaM kinase II (and the KN-92, as con-
trol) to test whether the effects of calmodulin can be medi-
ated through CaM kinase II. Figure 8A shows a dose-depen-
dent experiment with various KN-93 concentrations (5–100
M). Western blotting was then applied to analyze the
amount of phosphotyrosine produced. The same membrane
was then immunoblotted with anti–MEK-P. The results
showed that although there was an increased amount of
phosphotyrosine (anti–P-tyr), as shown for W-13, the
MEK-P was increased, contrary as demonstrated with W-13.
This indicated that calmodulin acts at two levels in the
MAPK signaling pathway. Interestingly, KN-93 did not
cause the accumulation of cargo in enlarged endosomes.
Finally, treatment with antibody-225 also inhibited the ty-
rosine phosphorylation of the EGFR and the MEK-P, in-
duced by KN-93 (Figure 8B).
We conclude that although CaM kinase II could be in-
volved in the transactivation of EGFR, it does not seem to
mediate the effect of W-13 on the Raf activity.
Calmodulin Inhibitors Induce the Cleavage of
Membrane Proteins
Recent data suggest that transactivation of EGFR occurs via
an autocrine/paracrine mechanism involving the release of
soluble EGF-like ligands (Getchtman et al., 1999; Prenzel et
al., 1999; Diaz-Rodriguez et al., 2000; Leserer et al., 2000).
These EGFR ligands require proteolytic release for their
biological activity. Metalloproteases are thought to be re-
sponsible for cleaving TGF, HB-EGF, amphiregulin, and
EGF. There is also evidence for the implication of the ADAM
(a disintegrin and metalloprotease) family of proteins in the
release of these ligands (Blobel, 1997).
To determine whether shedding could be responsible for
transactivation of EGFR-mediated activation of the ERK-P
cascade, we tested whether treatment with the metallopro-
tease inhibitor batimastat (BB94) interferes with the effect of
W-13 and/or KN-93.
Figure 9 shows that in COS-1 cells preincubated with BB94
(5 M) for 30 min, W-13 or KN-93 did not produce the
tyrosine phosphorylation of EGFR (Figure 9A). In addition,
BB94 completely inhibited MEK-P, in samples treated with
KN-93 (Figure 9B). The finding that batimastat impairs the
effect of W-13 and KN-93 on EGFR activation suggests that
Figure 5. The EGFR kinase activity is necessary for the W-13-
induced effects. COS-1 cells were preincubated with tyrphostin (1
M; A) or 10 g/ml Ab225 (B and C) for 20 min at 37°C. Then,
incubation was followed for 60 min with W-13 and/or 25 ng/ml
EGF for 10 min (A and B). An equal amount of protein was elec-
trophoresed and phosphotyrosine of EGF-R or MEK activation was
detected by Western blotting with antiphosphotyrosine RC-20 anti-
body HRP-conjugated or polyclonal antibody to phospho-MEK,
respectively.
Figure 6. W-13 effects on MAPK signaling pathway. Dissection of
the MAPK signaling pathway. Serum starved COS-1 cells grown in
100-mm dishes were incubated with W-13 (10 g/ml) for 60 min,
and the last 15 min with the indicated concentrations of EGF, at
37°C. Lysates with equal amount of protein were electrophoresed
and the stimulation of EGFR-phosphotyrosine (RC-20) (A), the Ras
activation (Ras-GTP) assessed by GST-RBD pull down (B), and the
MEK activation (C) were analyzed by Western blotting.
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shedding (through a CaM kinase II-dependent mechanism)
is necessary to activate EGFR.
DISCUSSION
Dissection of calmodulin-EGFR cross-communication led us
to the following conclusions. First, calmodulin may regulate
the form and the function of the endocytic compartment
responsible for EGFR trafficking; W-13 but not KN-93, me-
diates morphological changes in the early/sorting endocytic
compartment. Second, calmodulin and CaM kinase II may
modulate the shedding of autocrine/paracrine factor(s),
which, in turn may be involved in the transactivation of
EGFR. And third, calmodulin, but not CaM kinase II, is also
involved in the downstream effects of EGFR through the
regulation of Raf-1 activity, a convergence between Ca2
and Ras signaling pathways.
Second messengers such as cAMP and calmodulin are
involved in the regulation of intracellular trafficking, al-
though the specific molecular mechanisms and targets are
still unknown. Because several receptors, cytoskeleton com-
ponents, effectors and structural proteins of the membrane
trafficking machinery are known to be calmodulin-binding
proteins, calmodulin may play a key role in the transport
and delivery of membranes in the cell.
The use of calmodulin antagonist has been proved very
useful to study the role of calmodulin in different physio-
logical processes, including membrane trafficking
We and others have studied the role of calmodulin in the
various processes of membrane traffic: endocytosis (Apo-
daca et al., 1994; Llorente et al., 1996; Della Roca et al., 1999),
recycling (Apodaca et al., 1994; de Figueiredo and Brown,
1995; Huber et al., 2000), transcytosis (Apodaca et al., 1994;
Hunziker, 1994) at the completion of docking, and the late
Figure 7. W-13 inhibits Raf ac-
tivity. COS-1 cells serum starved
for 24 h were incubated with
W12 or W-13 (10 g/ml) for 60
min and/or 25 ng/ml EGF for
the last 10 min at 37°C. Raf ac-
tivity was measured, as de-
scribed in MATERIALS AND
METHODS, from the lysates by
immunoprecipitation with anti-
Raf antibody and kinase cascade
assay with GST-MEK, GST-
ERK2, and MBP as substrates.
(A) A representative experiment
assayed in triplicate and error
bars represent SD (n  3). (B) By
coimmunoprecipation, there is
no effect in the Ras-Raf interac-
tion after W-13 treatment. In C,
lysates from the same experi-
ment were probed with anti–P-
MEK.
Figure 8. Dose-dependent tyrosine phos-
phorylation of EGFR and MEK activation,
using the CaM kinase II inhibitor, KN-93.
COS-1 cells were incubated with the indi-
cated concentration of KN-93 or W-13 (10
g/ml) for 60 min at 37°C (A). An equal
amount of protein was electrophoresed and
analyzed with antiphosphotyrosine anti-
body (RC-20) or MEK activation detected
by Western blotting with antiphospho-
MEK. Also, COS-1 cells were preincubated
with10 g/ml Ab225 for 20 min at 37°C,
and the effect of KN-93 (50 M) is shown
(B).
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steps of vacuole fusion (Peters and Mayer, 1998). The spe-
cific effects of calmodulin antagonist were accompanied by
morphological changes in the endocytic compartments
(Apodaca et al., 1994; de Figueiredo and Brown, 1995;
Llorente et al., 1996). It was proposed that calmodulin an-
tagonist could inhibit the transport of receptors out of en-
dosomes by inhibiting the formation of the tubular-recycling
structures (de Figueiredo and Brown, 1995).
However, the mechanisms of W-13 inhibition of endoso-
mal function remain to be investigated. At least two possi-
bilities can be considered. First, the effects of W-13 can be
mediated through the components of the fusion-budding
machinery, such as annexins, EEA1, synaptobrevin (VAMP
2), or the PI3-K, which are either Ca2 or calmodulin-bind-
ing proteins. Second, calmodulin may control the endosomal
apparatus by the actin-cytoskeleton, through the GTPases of
the Rho or ARF subfamilies (e.g., Rac, ARF6; Hall, 1994;
Schmidt and Hall, 1998; Ridley, 2001) or through different
actin-associated, calmodulin-binding proteins (e.g., myr4;
Huber et al., 2000). The formation of aberrant endosomes
surrounded by actin, in W-13–treated cells could explain the
inhibition of fusion and fission processes in endosomes
(Apodaca, Tebar, and Enrich, unpublished data).
Interestingly, no studies analyze the effect of calmodulin
in EGFR trafficking. Because calmodulin antagonists modify
the structure of the endocytic compartment and stopped the
membrane trafficking in these aberrant early endocytic
structures, the inhibition of Raf-1 activity may result from
the blockage of EGFR in this early endocytic compartment.
Activated EGFR-Shc complexes, which initiate MAPK acti-
vation, are located predominantly along the endocytic path-
way (Di Guglielmo et al., 1994; Oksvold et al., 2000). More-
over, Raf-1 activation occurred in the early endosomes (Pol
et al., 1998; Rizzo et al., 1999, 2000). Ras and Raf-1 are
associated in caveolae (Mineo et al., 1996), at the cell surface,
but signals like EGF are probably responsible for their asso-
ciation and their ultimate transport to the endocytic com-
partment, where they achieve the signaling (Pol et al., 1998).
EGFR is a calmodulin-binding protein, and calmodulin
inhibits its tyrosine kinase activity (San Jose´ et al., 1992).
Calmodulin antagonists have been used in the analysis of
MAPK signaling pathway in PC12 cells, activated with NGF
or EGF. Egea et al. (2000) reported that W-13 abolishes the
initial Raf-1 activation without affecting upstream elements
like Ras, Grb2, Shc, or Trk. Calmodulin may thus regulate
the activation of Raf-1.
Here, we showed that although W-13 and KN-93 increase
the tyrosine phosphorylation of EGFR, only KN-93 activates
MEK and MAPK. On the other hand, W-13 and KN-93 show
differential behavior regarding the morphology of the endo-
cytic compartment, with the subsequent inhibition of recy-
cling. W-13 does not inhibit the functionality of the P-EGFR
because it associates with Shc in endosomes. At the same
time, W-13 inhibits Raf activity and, through stimulation of
a metalloprotease, induces the release of an unknown
growth factor, which subsequently activates the EGFR. In
fact, it has recently been demonstrated that calcium iono-
phores, calmodulin antagonists, and tyrosine phosphatase
inhibitors stimulate the release (shedding) by proteolysis of
EGFR ligands initially synthesized as integral membrane
precursor proteins (Kahn et al., 1998; Diaz-Rodriguez et al.,
2000; Dong and Wiley, 2000). Finally, a role of calmodulin in
mediating the transactivation of EGFR and ERK by the
opioid receptor or metalloprotease has recently been dem-
onstrated (Belcheva et al., 2001).
The sensitivity of molecules to calmodulin or the organi-
zation/assortment of CaMBPs in various cell lines may dif-
fer: W-13 induces a sustained activation of MAPK in
NIH3T3 cells compared with COS-1 cells (Bosch et al., 1998).
This contrasts with the effect of W-13 on COS-1 cells shown
in the present study and opens an intriguing question re-
garding the proteome of endosome, in various cell lines
specifically concerning the CaMBPs. In this study, we also
highlight that besides its morphological effects, which may
account for the blockage of recycling and transport to lyso-
somes, the endocytic compartment may also be the intracel-
lular scenario of signal transduction activation.
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